Glucose variability and low bone turnover in people with type 2 diabetes
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Fonden til Lægevidenskabens Fremme
- Novo Nordisk Fonden (NNF18OC0052064)
- Novo Nordisk Fonden (15-0542)
- Aase og Ejnar Danielsens Fond
- Health Research Fund of Central Denmark Region
This publication has 39 references indexed in Scilit:
- Diabetes and boneOsteoporosis and Sarcopenia, 2019
- Epidemiology of Fractures in DiabetesCalcified Tissue International, 2016
- Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cellsBiochemical and Biophysical Research Communications, 2015
- Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markersOsteoporosis International, 2014
- Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetesBone, 2013
- Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitroCurrent Medical Science, 2013
- Measures of Glycemic Variability and Links with Psychological FunctioningCurrent Diabetes Reports, 2010
- Four-month treatment with GLP-2 significantly increases hip BMDBone, 2009
- Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysisOsteoporosis International, 2006
- One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 DiabetesDiabetes, 2004